NexBio (R) presents data showing the anti-asthmatic DAS181 (Fludase (R)) In 2009 ACAA

NexBio, Inc. is a privately held clinical-stage biopharmaceutical company based in San Diego. NexBio mission is to save lives and improve the quality of life by creating and marketing a broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases. DAS181 is an investigational drug which is a recombinant fusion protein by inhalation. And ‘inactive viral receptors in cells of the human respiratory tract, in order to prevent and treat influenza infection, including potential pandemic strains, and parainfluenza viruses . DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health, under contract with BAA and grant U01-AI070281 HHSN266200600015C. TOSAP is a technology designed and developed by NexBio and is used to formulate DAS181 for inhalation, and nano / microparticles from any type of molecule. TOSAP is available for the formulation of compounds of partners under license.In particular, the current EPA 8-hour ozone is based on three year average of fourth highest concentration at each monitor, which must not exceed 75 ppb. Ozone concentrations in many urban areas of the United States, including metro Atlanta, routinely exceed the EPA standards.

This press release contains forward-looking information about the program of research and development of NexBio and efficacy of product candidates that may result from programs that involve risks and uncertainties. These risks and uncertainties include, among other things, the uncertainties inherent in research and development decisions by regulatory authorities regarding whether and when to allow clinical testing, or approval of any application that may result from drug programs and their decisions regarding labeling and other matters that could affect the commercial potential of product candidates that may result from this program, and competitive developments.

The new data presented from three studies in animal models, made by staff NexBio, demonstrate that DAS181 inhibits airway hyperreactivity characteristic of asthma. DAS181 further reduces the number of inflammatory cells and cells that secrete mucus in the airways. In animal models, DAS181 is as effective as a bronchodilator or a steroid that are anti-asthma drugs on the market. People with asthma are likely to develop serious complications when they get the flu.

According to the Centers for Disease Control and Prevention , the majority of hospitalizations for H1N1 flu pandemic is under way in asthmatics